Table 3. Toxicities of gefitinib and erlotinib as initial and retreatment therapy for patients with advanced NSCLC.

Toxicity	Initial treatment, n=33 (%)			Retreatment, n=33 (%)
	Grades 1-2	Grades 3-4		Grades 1-2	Grades 3-4
Rash	14 (42.4)	3 (9.1)		12 (36.4)	3 (9.1)
Fatigue	8 (24.2)	2 (6.1)		8 (24.2)	4 (12.1)
Diarrhoea	11 (33.3)	1 (3.0)		9 (27.3)	2 (6.1)
Nausea	10 (30.3)	1 (3.0)		10 (30.3)	2 (6.1)
Anorexia	6 (18.2)	1 (3.0)		6 (18.2)	3 (9.1)
Dyspnoea	3 (9.1)	2 (6.1)		3 (9.1)	2 (6.1)
Vomiting	5 (15.2)	1 (3.0)		7 (21.2)	1 (3.0)
Neurotoxicity	2 (6.1)	0 (0)		1 (3.0)	0 (0)
Cough	3 (9.1)	3 (9.1)		6 (18.2)	4 (12.1)
Stomatitis	3 (9.1)	1 (3.0)		3 (9.1)	3 (9.1)
Dry skin	5 (15.2)	3 (9.1)		1 (1.6)	0 (0.0)
Febrile neutropenia	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)
Hepatic injure	2 (6.1)	1 (3.0)		3 (9.1)	2 (9.1)